# US 2012/0251566 A1 · Saponin adjuvant compositions and methods relating thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251566 A1
- Document ID: US20120251566A1
- Status: Published application
- Kind: A1
- Application number: 13/420,082
- Filed: 2012-03-14
- Published: 2012-10-04
- Earliest claimed: 1999-01-08
- Assignees: Pfizer Inc.
- Inventors: John Walker
- Web page: https://patentgrep.com/patent/US20120251566A1

## CPC

- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 39/0006: {Contraceptive vaccins; Vaccines against sex hormones}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 5/02: of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/16: Masculine contraceptives
- A61P 15/18: Feminine contraceptives
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/55583: {Polysaccharides}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An adjuvant composition which comprises an anionic macromolecule component particularly an ionic polysaccharide such as DEAE-dextran, and a saponin component, particularly an immunostimulating complex component. Immunogenic compositions comprising an immunogen and this adjuvant composition are also disclosed together with methods of use thereof.

## Claims

### Claim 1

An adjuvant composition consisting of an ionic polysaccharide component and a saponin component, wherein the saponin component is provided in the form of an immunostimulatory complex.

### Claim 2 (depends on 1)

The adjuvant composition of claim 1, wherein an ionic polysaccharide is an ionic dextran.

### Claim 3 (depends on 2)

The adjuvant composition of claim 2, wherein an ionic dextran is DEAE-dextran or QAE-dextran.

### Claim 4 (depends on 1)

The adjuvant composition of claim 1, wherein the immunostimulating complex is a protein-free immunostimulating complex.

### Claim 5 (depends on 1)

The adjuvant composition of claim 1, wherein the immunostimulating complex comprises cholesterol, phosphatidyl choline, and Quil A.

### Claim 6 (depends on 1)

The adjuvant composition of claim 1, wherein the mass ratio of ionic polysaccharide component to immunostimulating complex component is in the range of about 100 to about 140.

### Claim 7 (depends on 6)

The adjuvant composition of claim 6, wherein the mass ratio is about 125.

### Claim 8 (depends on 1)

The adjuvant composition of claim 1, comprising about 10 mg of the ionic polysaccharide and about 80 μg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.

### Claim 9 (depends on 1)

The adjuvant composition of claim 1, comprising about 100 mg of the ionic polysaccharide and about 800 μg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.

### Claim 10 (depends on 1)

An immunogenic composition comprising an immunogen and the adjuvant composition of claim 1.

### Claim 11 (depends on 10)

The immunogenic composition of claim 10, wherein said immunogen comprises LHRH.

### Claim 12 (depends on 11)

The immunogenic composition of claim 11, wherein said immunogen comprises an LHRH-diphtheria toxoid conjugate.

### Claim 13 (depends on 12)

The immunogenic composition of claim 12, comprising from about 5 to about 500 μg of LHRH-diphtheria toxoid conjugate, from about 5 to about 500 mg of the ionic polysaccharide, and from about 40 to about 4000 μg of the immunostimulating complex.

### Claim 14 (depends on 10)

A vaccine comprising (i) the immunogenic composition of claim 10, and (ii) one or more pharmaceutically acceptable carriers.

### Claim 15 (depends on 14)

A method of eliciting an effective immune response in an animal, comprising administering to an animal an effective amount of the vaccine of claim 14.

### Claim 16 (depends on 1)

The adjuvant composition of claim 1, wherein the mass ratio of the ionic polysaccharide component to the immunostimulating complex component is in the range of 50 to 300.

### Claim 17

An adjuvant composition comprising an ionic polysaccharide component and a saponin component, wherein the saponin component is provided in the form of an immunostimulatory complex.

### Claim 18 (depends on 17)

The adjuvant composition of claim 17, wherein an ionic dextran is DEAE-dextran or QAE-dextran.

### Claim 19 (depends on 17)

The adjuvant composition of claim 17, wherein the immunostimulating complex comprises cholesterol, phosphatidyl choline, and Quil A.

### Claim 20 (depends on 17)

An immunogenic composition comprising an immunogen and the adjuvant composition of claim 17.

### Claim 21 (depends on 20)

A vaccine comprising (i) the immunogenic composition of claim 20, and (ii) one or more pharmaceutically acceptable carriers.

### Claim 22 (depends on 21)

A method of eliciting an effective immune response in an animal, comprising administering to an animal an effective amount of the vaccine of claim 21.

### Claim 23

An adjuvant composition consisting of an ionic polysaccharide component and a saponin component, wherein the saponin component is provided in the form of an immunostimulatory complex, wherein the immunostimulatory complex is a cage-like structure.
